HARBIN, China, Oct. 21 /Xinhua-PRNewswire-FirstCall/ -- China Sky One Medical, Inc. ("China Sky One Medical" or "the Company") (Nasdaq: CSKI), a leading fully integrated pharmaceutical company producing over-the-counter drugs in the People's Republic of China ("PRC"), announced today that the Company's wholly-owned subsidiary, Harbin First Bio-Engineering Co. Ltd. ("Harbin First Bio-Engineering"), received $800,000 in tax savings from the Heilongjiang Binxi Economic Zone.
China Sky One Medical entered into an agreement with the Heilongjiang Binxi Economic Zone in 2005, when the Company decided to invest in Harbin First Bio-Engineering. Under the agreement, the Heilongjiang Binxi Economic Zone agreed to provide fiscal support by refunding local income taxes for Harbin First Bio-Engineering until 2010. As a result, Harbin First Bio-Engineering received a 2007 local income tax refund of $800,000 in October, 2008.
"We are pleased to obtain local government fiscal support from the Heilongiang Binxi Economic Zone," said Mr. Yan-qing Liu, Chairman, CEO and President of China Sky One Medical. "We will invest this refund back into our business in order to further improve operations and carry out our growth strategy of strengthening our distribution channel and developing exciting new drugs."
About China Sky One Medical, Inc.
China Sky One Medical, Inc., a Nevada corporation, is a holding company. The Company engages in the manufacturing, marketing and distribution of pharmaceutical, medicinal and diagnostic products. Through its wholly-owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio-Engineering Company Limited, and Heilongjiang Tianlong Pharmaceutical, Inc., the Company manufactures and distributes over-the-counter pharmaceutical products, which make up its major revenue source. For more information, visit http://www.skyonemedical.com .
Safe Harbor Statement
Certain of the statements made in the press release constitute forward-
looking statements within the meaning of the Private Securities Litigation
Reform Act of 1995. These statements can be identified by the use of
forward- looking terminology such as "believe," "expect," "may," "will,"
"should," "project," "plan," "seek," "intend," or "anticipate" or the
negative thereof or comparable terminology. Such statements typically
involve risks and uncertainties and may include financial projections or
information regarding our future plans, objectives or performance. Actual
results could differ materially from the expectations reflected in such
forward-looking statements as a result of a variety of factors, including
the risks associated with the effect of changing economic conditions in The
People's Republic of China, variations in cash flow, reliance on
collaborative retail partners and on new product development, variations in
new product development, risks associated with rapid technological change,
and the potential of introduced or undetected flaws and defects in
products, and other risk factors detailed in reports filed with the
Securities and Exchange Commission from time to time.
For more information, please contact:
China Sky One Medical, Inc.
Mr. Yu-Bo Hao, Board Secretary
Investor Relations Contact:
CCG Investor Relations
Mr. Crocerk Coulson, President
|SOURCE China Sky One Medical, Inc.|
Copyright©2008 PR Newswire.
All rights reserved